Stockreport

MindMed Reports Q3 2025 Financial Results and Business Updates

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF -- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)---- [Read more]